(Q37614572)

21 August 2017

1 reference

title

Combination of radiotherapy and chemotherapy in locally advanced NSCLC. (English)

1 reference

adaptive radiation therapy

21 August 2017

main subject

0 references

1 reference

Lucyna Kepka

1

1 reference

21 August 2017

Arkadiusz Sprawka

2

1 reference

21 August 2017

Francesc Casas

3

1 reference

21 August 2017

Sherif Abdel-Wahab

4

1 reference

21 August 2017

Jai Prakash Agarwal

5

1 reference

21 August 2017

Branislav Jeremic

6

1 reference

21 August 2017

language of work or name

1 reference

1 October 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1389-1403

1 reference

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Biologic basis for combining drugs with radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Current treatment paradigms for locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-c

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-sm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Low incidence of isolated nodal failures after involved-field radiation therapy for non small-cell lung cancer: blinded by the light?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.121

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD004569.PUB2

Identifiers

DOI

10.1586/ERA.09.121

1 reference

21 August 2017

1 reference